Acute myeloid leukemia Trials in Nashville, United States
Conditions / Acute myeloid leukemia / Nashville, United States
Research into Acute myeloid leukemia spans multiple therapeutic approaches and trial phases.
78 total trials for this combination
Showing top 10 of 78 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | TERMINATED | PHASE1 |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | COMPLETED | PHASE1 |
| NCT04726241 | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | RECRUITING | PHASE1/PHASE2 |
| NCT01307579 | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia | COMPLETED | PHASE3 |
| NCT02521493 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04293562 | A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | RECRUITING | PHASE3 |
| NCT01802333 | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | COMPLETED | PHASE3 |
| NCT01371981 | Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06001385 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | TERMINATED | PHASE1 |